Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the clinical activity and safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-induction therapy in adult patients with WT1-positive AML presenting a suboptimal clinical response to induction chemotherapy. The study will also assess whether this treatment induces a specific immune response to the malignancy.


Clinical Trial Description

At least 40 patients will be enrolled in this study, divided in two cohorts of 20 patients each. One cohort will include patients in partial remission after induction therapy and one cohort will include patients in complete remission but with incomplete blood count recovery. Patients in both cohorts will receive the same study treatment according to the same administration schedule.

This protocol summary has been updated according to the Protocol Amendment 3 (dated 10 Sept 2014).

All active follow-up visits and procedures after the concluding visit, 30 days after the last treatment administration, will be stopped In addition, no more biological samples will be collected for protocol research purposes. For each biological sample already collected in the scope of this study and not tested yet, testing will not be performed by default, except if a scientific rationale remains relevant.Blood sampling for safety monitoring as per protocol will continue. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01051063
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date December 9, 2009
Completion date April 26, 2016

See also
  Status Clinical Trial Phase
Completed NCT00725283 - Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) Phase 1
Terminated NCT02177812 - A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) Phase 1
Completed NCT01428427 - Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors Phase 1